The long-term natural history of gastroesophageal reflux disease

Journal of Clinical Gastroenterology

Volumn 40, Issue 5, 2006, Pages 398-404

  Sontag, Stephen J ^a,b   Sonnenberg, Amnon ^c   Schnell, Thomas G ^a,b   Leya, Jack ^a,b   Metz, Adrienne ^a  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Gastroesophageal reflux diseases; Natural history

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ANTIREFLUX OPERATION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOSCOPY; ESOPHAGUS MUCOSA; ESOPHAGUS STRICTURE; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 33748283314     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200605000-00007     Document Type: Article

References (16)

1. Ollyo JP, Monnier P, Fontolliet C, et al. The natural history of prevalence and incidence of reflux oesophagitis. Gullet. 1993;3(Suppl 1):3-10.
2. Monnier P, Ollyo JP Fontolliet C, et al. Epidemiology and natural history of reflux esophagitis. Sem Lap Surg. 1995;1:2-9.
3. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
4. Gallup Organization National Survey. Heartburn Across America. Princeton, NJ: Gallup Organization; 1988.
5. Smout AJ. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther. 1997;11(Suppl 12):81-85.
6. Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow-up of patients with gastroesophageal reflux disease. Gut. 1992;33:1016-1019.
7. Wilkins WE, Ridley MG, Pozniak AL. Benign stricture of the oesophagus: Role of non-steroidal anti-inflammatory drugs. Gut. 1984;25:478-480.
8. Lanas A, Hirschowitz BI. Significant role of aspirin use in patients with esophagitis. J Clin Gastroenterol. 1991;13:622-627.
9. El-Serag HB, Sonnenberg A. Non-steroidal anti-inflammatory drugs represent risk factors of erosions and peptic strictures of the esophagus. Am J Gastroenterol. 1997;92:57-60.
10. Avidan B, Sonnenberg A, Schnell TG, et al. Risk Factors of oesophagitis in arthritic patients. Eur J Gastroenterol Hepatol. 2001;13:1095-1099.
11. Avidan B, Sonnenberg A, Schnell TG, et al. Risk factors for erosive reflux esophagitis: A case-control study. Am J Gastroenterol. 2001;96:41-46.
12. Weinstein WM. Erosive esophagitis impairs accurate detection of Barrett's esophagitis: a prospective randomized, double-blind study. Gastroenterology. 1999;116:A352.
13. Singh P, Taylor RH, Colin-Jones DG. Prolonged remission of oesophagitis does not alter the magnitude of oesophageal acid exposure. Scand J Gastroenterol. 1994;29:11-16.
14. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol. 1997;92:37-41.
15. Pace F. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut. 1991;32:845-848.
16. Pace F. Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD): a reappraisal 10 years on. Dig Liver Dis. 2004;36:111-115.